In this episode of #OncoDaily, host Dr. Sergey Badalyan sits down with Dr. Kimberly Sabelko, Vice President of Scientific Strategy and Programs at Susan G. Komen, to discuss the organization’s newly announced $15.4 million investment in #breastcancer research across 24 leading U.S. institutions.
The conversation explores why metastatic breast cancer remains the organization’s top priority, how #precisionmedicine and artificial intelligence are reshaping treatment, the promise of vaccine-based therapies, and why supporting early-career researchers is essential for future breakthroughs.
Dr. Sabelko also explains how patient voices influence research funding decisions and why sustained investment is critical to accelerating progress against breast cancer.